China’s Simcere Gains Regional Rights for Two Alzheimer’s Drugs
The market for Alzheimer’s disease (AD) drugs in China is estimated to reach $2 billion by 2027 with a CAGR of 10.3%, outpacing several big economies such as Japan, Canada, …
Read MoreThe Next Generation Biotech Media
The market for Alzheimer’s disease (AD) drugs in China is estimated to reach $2 billion by 2027 with a CAGR of 10.3%, outpacing several big economies such as Japan, Canada, …
Read MoreCancer is on its way to becoming the leading cause of mortality as a result of extended lifespan, lifestyle choices, and risk factors in the environment. Most cancers can be …
Read MoreSouth Korea was slow on COVID-19 vaccine development. Until recently, none of the indigenously developed COVID-19 vaccines had reached Phase 3 clinical trials. Genexine’s GX-19 was the fastest in terms …
Read MoreOn June 28th, Kite, a company of Gilead, announced that Yescarta, a CAR-T therapy improved event-free survival when compared with second-line standard of care therapy in relapsed or refractory large …
Read MoreSouth Korea has become a global hub for COVID-19 vaccine manufacturing. After Moderna and Novavax made deals with the Korean government in May to produce their vaccines, the country’s pharma …
Read MoreOn June 24th, AbbVie decided to acquire TeneoOne, a subsidiary of Teneobio, to lay hands on the latter’s new multiple myeloma drug, TNB-383B. Earlier in 2019, the two companies had …
Read MoreLow-calorie diets are popular and fairly effective weight loss strategies. However, severe caloric restriction has more effects on the human body than just fat loss. It contributes to drastic changes …
Read MoreChina broke the status quo by approving the country’s first CAR-T therapy on June 23rd. Fosun Kite Biotechnology, the joint venture of Kite Pharma and China’s Fosun Pharmaceutical, received approval …
Read MoreOctober 26th, 2021 – Intellia Therapeutics, a gene-editing company co-founded by Nobel laureate, Jennifer Doudna, created history today, revealing the first-ever clinical proof for directly editing human genomes using the …
Read MoreKRAS is a major cancer driver mutated in around 30%-40% of colon cancers and 15%-20% of lung cancers. Developing inhibitors for KRAS is a challenge, and until very recently, KRAS …
Read More